retatrutide fda approval status clinical data 2026: Everything We Know So Far Retatrutide clinical trial done! Now – ⚠️ Before you consider using

While prior large-scale studies earlier in 2024 did not find an association between GLP-1 receptor agonists and retinopathy, this recent case series suggests that a subset of patients may be vulnerable to optic nerve damage and other vision complications [1,2]

Heart medications can significantly improve cardiovascular health, but they sometimes lead to weight gain as a side effect

According to clinical trial data and post-marketing surveillance, these effects are generally dose-dependent (more common with higher doses) and tend to diminish over time as the body adapts to the medication

Additional syringe features to consider Needle gauge: 30G and 32G are standard for subcutaneous peptide injections